Treatment of intraocular lymphoma with high-dose Ara-C
- 1 April 1986
- Vol. 57 (7), 1273-1275
- https://doi.org/10.1002/1097-0142(19860401)57:7<1273::aid-cncr2820570702>3.0.co;2-c
Abstract
Ocular lymphoma is an uncommon clinical entity with a propensity for intracranial extension. Palliation has been reported following radiotherapybut the ultimate prognosis is poorand significant treatment‐related morbidity is common. Recent pharmacokinetic studies have suggested that sustained therapeutic drug concentrations are achievable in cerebrospinal fluid after systemic administration of high‐dose cytosine arabinoside (Ara‐C). These data led the authors to attempt treatment of a case of recurrent ocular lymphoma with high‐dose Ara‐C. Therapeutic drug levels were documented in intraocular fluidsand prolonged objective regression of tumor was seen. Systemic high‐dose Ara‐C deserves consideration for the treatment of ocular lymphoma.This publication has 12 references indexed in Scilit:
- Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.Journal of Clinical Oncology, 1983
- Ocular toxicity from high-dose cytosine arabinosideCancer, 1983
- Radiation Optic NeuropathyOphthalmology, 1982
- Radiation RetinopathyOphthalmology, 1982
- The role of radiation therapy in the management of ocular reticulum cell sarcomaCancer, 1980
- A clinicopathologic study of orbital and adnexal non-Hodgkin's lymphomaCancer, 1979
- Determination of cytosine arabinoside in human plasma by high-pressure liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1978
- Primary malignant lymphomas of the central nervous systemCancer, 1974
- Clinical pharmacology of l‐β‐D‐arabinofuranosyl cytosineClinical Pharmacology & Therapeutics, 1971
- Choroido-Retinal Damage as A Complication of RadiotherapyActa Radiologica: Therapy, Physics, Biology, 1965